13 X is among the least developed countries recognized by the United Nations. Since the bird flu has
been spreading over the country over six months and the toll of death is astonishingly
increasing. In order to import sufficient and affordable medicine to assuage the damage of the
pandemic, X plans to negotiate with Taiwanese pharmacy company Y, and asks Y to apply for the
compulsory licensing on Patent M registered in Taiwan that embodies the medicine B for treating
the aforesaid bird flu. According to the Taiwan Patent Act, which of the following statements is
appropriate?
(A) Y is not entitled to request the compulsory licensing on Patent M since the bird flu is not the
disease defined in Article 90 of Taiwan Patent Act.
(B) Y is not entitled to request the compulsory licensing on Patent M since the provisions of the
compulsory licensing are designed to mainly facilitate the demand in the domestic market.
(C) Y is entitled to request the compulsory licensing on Patent M, provided that X could prove that
it has insufficient or no manufacturing capacities in the pharmaceutical.
(D) Y is not entitled to request the compulsory licensing on Patent M unless Y has made efforts to
obtain authorization from the patentee concerned on reasonable commercial terms and
conditions and such efforts have not been successful within a reasonable period of time.